| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $3,928,064 | 6 | 100 |
| GANNON STEVEN | director | 0 | $0 | 1 | $91 | $-91 |
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | 0 | $0 | 5 | $3.93M | $-3.93M |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Over the last 12 months, insiders at Xenon Pharmaceuticals Inc. have bought $0 and sold $3.93M worth of Xenon Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Xenon Pharmaceuticals Inc. have bought $235,534 and sold $5.31M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,400 shares for transaction amount of $40,334 was made by KENNEY CHRISTOPHER JOHN (Chief Medical Officer) on 2022‑01‑21.
| 2026-01-02 | Sale | MORTIMER IAN | PRESIDENT & CEO | 40,000 0.0513% | $44.43 | $1.78M | -6.16% | |
| 2025-12-08 | Sale | MORTIMER IAN | PRESIDENT & CEO | 10,830 0.0144% | $45.73 | $495,207 | -5.14% | |
| 2025-12-05 | Sale | MORTIMER IAN | PRESIDENT & CEO | 14,375 0.0186% | $45.03 | $647,306 | -6.10% | |
| 2025-11-28 | Sale | MORTIMER IAN | PRESIDENT & CEO | 97 0.0001% | $45.01 | $4,366 | -5.12% | |
| 2025-10-01 | Sale | MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | 25,000 0.0324% | $40.16 | $1M | +7.13% | |
| 2025-06-05 | Sale | GANNON STEVEN | director | 3 <0.0001% | $30.48 | $91 | +27.89% | |
| 2025-01-27 | Sale | MORTIMER IAN | PRESIDENT & CEO | 16,315 0.0216% | $40.50 | $660,806 | -5.71% | |
| 2025-01-24 | Sale | MORTIMER IAN | PRESIDENT & CEO | 22,468 0.0298% | $40.20 | $903,214 | -5.41% | |
| 2025-01-23 | Sale | MORTIMER IAN | PRESIDENT & CEO | 16,217 0.0213% | $40.08 | $649,977 | -5.40% | |
| 2024-12-18 | Sale | AULIN SHERRY | Chief Financial Officer | 18,709 0.0256% | $41.21 | $770,912 | -3.96% | |
| 2024-11-22 | Sale | PATOU GARY | director | 4,891 0.0064% | $41.09 | $200,947 | -8.24% | |
| 2024-03-08 | Sale | GAROFALO ELIZABETH A. | director | 2,092 0.0027% | $45.69 | $95,583 | -13.08% | |
| 2024-03-07 | Sale | ROBIN SHERRINGTON | EVP, Strategy & Innovation | 7,137 0.0095% | $46.28 | $330,290 | -12.81% | |
| 2024-03-07 | Sale | GANNON STEVEN | director | 13,000 0.0173% | $46.28 | $601,615 | -12.81% | |
| 2023-12-14 | Sale | PATOU GARY | director | 7,598 0.0103% | $41.05 | $311,898 | +1.21% | |
| 2023-12-13 | Sale | PATOU GARY | director | 18,978 0.0257% | $39.99 | $758,983 | +4.60% | |
| 2023-08-24 | Sale | Svoronos Dawn | director | 25,000 0.0391% | $38.70 | $967,500 | +4.70% | |
| 2023-06-01 | Sale | PIMSTONE SIMON N. | director | 31,713 0.0485% | $38.82 | $1.23M | +2.56% | |
| 2023-05-31 | Sale | PIMSTONE SIMON N. | director | 62,526 0.0956% | $38.70 | $2.42M | +2.70% | |
| 2023-05-30 | Sale | PIMSTONE SIMON N. | director | 37,006 0.0576% | $39.28 | $1.45M | +3.13% |
| GANNON STEVEN | director | 7141 0.0092% | $297,779.70 | 1 | 2 | +31.48% |
| MORTIMER IAN | PRESIDENT & CEO | 6000 0.0078% | $250,200.00 | 2 | 9 | +28.18% |
| BVF PARTNERS L P/IL | 10 percent owner | 1674468 2.1669% | $69.83M | 10 | 0 | <0.0001% |
| Hayden Michael R | director | 161187 0.2086% | $6.72M | 1 | 0 | +44.6% |
| HOLLER FRANK A | director | 143653 0.1859% | $5.99M | 0 | 10 | |
| AZAB MOHAMMAD | director | 57561 0.0745% | $2.4M | 5 | 1 | +72.32% |
| Svoronos Dawn | director | 25000 0.0324% | $1.04M | 1 | 1 | +44.6% |
| PATOU GARY | director | 23573 0.0305% | $982,994.10 | 2 | 4 | +22.11% |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 10000 0.0129% | $417,000.00 | 1 | 3 | +48.57% |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 8398 0.0109% | $350,196.60 | 0 | 4 | |
| SCHELLER RICHARD H | director | 7000 0.0091% | $291,900.00 | 1 | 0 | +28.18% |
| GOLDBERG Y. PAUL | VP of Clinical Development | 6000 0.0078% | $250,200.00 | 0 | 3 | |
| PIMSTONE SIMON N. | director | 6000 0.0078% | $250,200.00 | 1 | 12 | +28.18% |
| Von Seggern Christopher | Chief Commercial Officer | 4000 0.0052% | $166,800.00 | 1 | 0 | +29.4% |
| WINQUIST RAYMOND | Head, Translational Research | 1000 0.0013% | $41,700.00 | 1 | 0 | +25.42% |
| GAROFALO ELIZABETH A. | director | 0 0% | $0 | 0 | 1 | |
| AULIN SHERRY | Chief Financial Officer | 0 0% | $0 | 0 | 2 | |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 0 0% | $0 | 1 | 1 | +29.65% |
$66,736,176 | 136 | 27.54% | $3.69B | |
$52,263,649 | 70 | 1.18% | $3.8B | |
$11,588,217 | 69 | 42.07% | $3.03B | |
$104,428,685 | 44 | 22.55% | $2.94B | |
$148,770,544 | 34 | 80.63% | $3B | |
$61,717,660 | 28 | 36.84% | $3.57B | |
Xenon Pharmaceuticals Inc. (XENE) | $5,066,938 | 27 | 26.38% | $3.22B |
$150,253,463 | 26 | -52.83% | $3.35B | |
$27,105,902 | 21 | -16.06% | $3.85B | |
$137,061,250 | 16 | 23.01% | $3.26B | |
$174,105,409 | 15 | 10.88% | $2.73B | |
$92,580,864 | 14 | -1.28% | $3.18B | |
$1,248,715 | 10 | 5.66% | $2.85B | |
$1,711,150 | 9 | 31.59% | $3.52B | |
$45,445,266 | 9 | -24.96% | $2.7B | |
$32,575,266 | 8 | 37.03% | $2.66B | |
$142,493,653 | 3 | 4.30% | $3.33B | |
$50,990,767 | 2 | 19.79% | $3.82B | |
$9,900,000 | 1 | -7.19% | $3.01B |
| Increased Positions | 121 | +51.49% | 10M | +12.69% |
| Decreased Positions | 97 | -41.28% | 7M | -8.7% |
| New Positions | 45 | New | 2M | New |
| Sold Out Positions | 22 | Sold Out | 805,890 | Sold Out |
| Total Postitions | 259 | +10.21% | 85M | +3.99% |
| Fmr Llc | $396,802.00 | 11.58% | 8.92M | +34,544 | +0.39% | 2025-09-30 |
| Avoro Capital Advisors Llc | $240,246.00 | 7.01% | 5.4M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $212,260.00 | 6.2% | 4.77M | -594,376 | -11.08% | 2025-09-30 |
| Driehaus Capital Management Llc | $185,484.00 | 5.41% | 4.17M | -166,534 | -3.84% | 2025-09-30 |
| Janus Henderson Group Plc | $175,463.00 | 5.12% | 3.94M | +366,150 | +10.23% | 2025-09-30 |
| Wellington Management Group Llp | $160,603.00 | 4.69% | 3.61M | +1M | +65.99% | 2025-09-30 |
| Braidwell Lp | $160,388.00 | 4.68% | 3.61M | 0 | 0% | 2025-09-30 |
| Capital International Investors | $141,545.00 | 4.13% | 3.18M | -56 | <0.01% | 2025-09-30 |
| Commodore Capital Lp | $120,123.00 | 3.51% | 2.7M | -325,000 | -10.74% | 2025-09-30 |
| Polar Capital Holdings Plc | $113,306.00 | 3.31% | 2.55M | -156,490 | -5.79% | 2025-09-30 |